Magenta Therapeutics
Magenta Therapeutics is a biotechnology company using stem cells to develop cellular therapies for immune and blood-based diseases.
All edits
April 9, 2018
On April 9, 2018 Magenta Therapeutics completed their series C funding round with $52 million in funding from Casidin Capital (lead investor), The Watermill Group, Eventide Asset Management, EcoR1 Capital, Be The Match BioTherapies, and Access Industries.
May 2, 2017
On May 2, 2017 Magenta Therapeutics completed their series B funding round with $50 million in funding from GV (lead investor), Third Rock Ventures, Partners Innovation Fund, Casidin Capital, Atlas Ventures, and Access Industries.
November 16, 2016
On November 16, 2016 Magenta Therapeutics completed their series A funding round with $48.5 in funding from Third Rock Ventures and Atlas Ventures.
On November 16, 2016 Magenta Therapeutics completed their series A funding round with $48.5 in funding from Third Rock Ventures and Atlas Ventures.
On May 2, 2017 Magenta Therapeutics completed their series B funding round with $50 million in funding from GV (lead investor), Third Rock Ventures, Partners Innovation Fund, Casidin Capital, Atlas Ventures, and Access Industries.
On April 9, 2018 Magenta Therapeutics completed their series C funding round with $52 million in funding from Casidin Capital (lead investor), The Watermill Group, Eventide Asset Management, EcoR1 Capital, Be The Match BioTherapies, and Access Industries.
Find more companies like Magenta Therapeutics
